지카바이러스 치료 시장 규모, 점유율, 성장 분석 : 백신 유형별, 검사 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Zika Virus Therapeutics Market size was valued at USD 2.27 Billion in 2024 and is poised to grow from USD 2.58 Billion in 2025 to USD 7.16 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).

The global Zika virus therapeutics market is experiencing robust growth, driven by rising infection rates, intensified research and development efforts, and heightened public awareness regarding prevention and vaccination. The virus, predominantly transmitted by mosquitoes, poses significant risks including severe birth defects and neurological disorders, particularly in tropical and subtropical areas, thereby fueling demand. Technological advancements such as mRNA technology and digital monitoring frameworks are accelerating vaccine development and enhancing safety. Additionally, government initiatives aimed at Zika prevention are amplifying demand. The integration of AI, machine learning, blockchain, and IoT into vaccine production and logistics is revolutionizing the sector by improving efficiency, forecasting outbreaks, ensuring transparency in distribution, and bolstering public education on prevention and treatment strategies, ultimately reshaping market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Zika Virus Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Zika Virus Therapeutics Market Segments Analysis

Global Zika Virus Therapeutics Market is segmented by Vaccine Type, Test Type, End User, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Virus Vaccine, Live Attenuated Vaccine, DNA Vaccine and mRNA Vaccine. Based on Test Type, the market is segmented into Molecular Test and Serological Test. Based on End User, the market is segmented into Hospitals and Clinics and Research Institutes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Zika Virus Therapeutics Market

The rising incidence of Zika virus, especially in tropical and subtropical areas, is being driven by factors such as increased global travel, climate change, urbanization, and a growing mosquito population. These elements collectively heighten the urgency for effective prevention and treatment options for the virus. In response, both governments and international health organizations are significantly increasing their investments in Zika virus prevention efforts, thereby elevating the demand for therapeutics aimed at addressing this public health challenge. This escalating focus on Zika virus control is further stimulating growth in the global market for related treatments and preventive measures.

Restraints in the Global Zika Virus Therapeutics Market

The development of therapeutics for the Zika virus faces significant challenges, primarily driven by the high costs associated with extensive research and multiple clinical trials prior to market introduction. Various regulatory bodies impose differing acceptance criteria, necessitating additional research and financial investment to meet compliance requirements. Furthermore, several of the vaccine candidates demand cold storage and robust cold chain logistics, which further escalates operational expenses. These factors collectively create substantial barriers that could hinder the growth and accessibility of Zika virus therapeutics, impacting the overall market potential.

Market Trends of the Global Zika Virus Therapeutics Market

The Global Zika Virus Therapeutics market is witnessing a significant trend driven by advancements in vaccine technology, particularly the emergence of mRNA and DNA-based platforms. These innovative approaches facilitate quicker and more efficient vaccine development, enabling companies to respond rapidly to public health needs. Regulatory bodies and medical organizations are increasingly endorsing these new technologies, which enhances market acceptance and adoption of Zika vaccines. This trend not only accelerates the availability of effective therapeutics but also fosters collaboration among biopharmaceutical firms, research institutions, and governments, ultimately contributing to a robust pipeline aimed at combatting Zika Virus outbreaks globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Zika Virus Therapeutics Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Inactivated Virus Vaccine
• Live Attenuated Vaccine
• DNA Vaccine
• mRNA Vaccine

Global Zika Virus Therapeutics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Molecular Test
• Serological Test

Global Zika Virus Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Research Institutes

Global Zika Virus Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Zika Virus Therapeutics Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Test Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Test Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Test Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Test Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Test Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Moderna Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kimer Med (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVaxys Technology Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations